OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Kathleen Moore, MD, Stephenson Cancer Center

home / authors / kathleen-moore-md-stephenson-cancer-center

Articles

Advertisement

Promising Novel Targets for Endometrial Cancer Management

Promising Novel Targets for Endometrial Cancer Management

February 4th 2021

Read More


Novel Strategies in Development for EC Management

Novel Strategies in Development for EC Management

February 4th 2021

Read More


Therapy Sequencing Through Multiple Lines of Therapy in EC

Therapy Sequencing Through Multiple Lines of Therapy in EC

February 4th 2021

Read More


Impact of Pembrolizumab/Lenvatinib Approval in EC

Impact of Pembrolizumab/Lenvatinib Approval in EC

February 4th 2021

Read More


Safety/Efficacy Results From EC Cohort of KEYNOTE-146

Safety/Efficacy Results From EC Cohort of KEYNOTE-146

February 4th 2021

Read More


Rationale for Combination Therapy in Advanced EC

Rationale for Combination Therapy in Advanced EC

February 4th 2021

Read More

Advertisement

GARNET Clinical Trial Regimen in Advanced Disease

GARNET Clinical Trial Regimen in Advanced Disease

February 4th 2021

Read More


Second-Line Checkpoint Inhibitor for MSI-H Disease

Second-Line Checkpoint Inhibitor for MSI-H Disease

February 4th 2021

Read More


Adjuvant Chemotherapy +/- Radiotherapy: Recent Data

Adjuvant Chemotherapy +/- Radiotherapy: Recent Data

February 4th 2021

Read More


Treatment Challenges: Advanced Endometrial Cancer

Treatment Challenges: Advanced Endometrial Cancer

February 4th 2021

Read More


Genomic Assessments for Metastatic Disease

Genomic Assessments for Metastatic Disease

January 29th 2021

Read More


Endometrial Cancer Incidence and Risk Classification

Endometrial Cancer Incidence and Risk Classification

January 29th 2021

Read More

Latest Conference Coverage

Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact